Thank you, Jens, and thanks for the introduction. Also about what has been going on when it comes to Fostrox.
But just as a reminder, the FLEX-HCC study that is the reason why we went to Korea is a randomized, second line study in liver cancer.
And it's really there to strengthen the evidence that we have from our single arm trial with Fostrox plus Lenvima in liver cancer, and to show superiority over Lenvima alone.
So just as a reminder, what this study is, is that Fostrox is combined with Lenvima in one arm, and it's randomized against Lenvima monotherapy in the other arm, and 80 patients will be enrolled in this study, who have progressed or are intolerant to prior immunotherapy combinations. And as Jens said, the patients will now be enrolled at 12 sites instead of the original eight sites, due to high interest. And the PI for the study is Professor Hong Jae Chon from CHA Bundang Hospital, and he is doing this study in close collaboration with the Korean Cancer Study Group, and I think that is also the reason why there is a high interest, because this group recently executed and also published, actually, the only prospective study with lenvatinib monotherapy in a similar patient population that will be enrolled in the FLEX-HCC study.
So it's a really, really nice setup.
And here, patient enrollment is expected to take around 12 months, and the primary endpoint will be evaluated by a blinded, independent central review to make sure that we have the quality that is required to really show this difference. And since we hope this study will enroll and perform relatively quickly, the topline results are expected already in 2027.
We had the opportunity to visit eight of the 12 sites last week in Korea. And right now two of the sites are open for enrollment and that is Cha Bundang, where Professor Chon is situated, and Severance Hospital. And we know that they are super eager to have the first patient in. And as you can see on this map here, if you can see it, the site is geographically spread across Korea also to have the best chance of capturing all the patients that could be eligible for this study.
And since we had the opportunity now to discuss with the investigators, it became really, really clear that there is a very high interest in participating in this study and that they have quite a few second-line patients every week that potentially could be candidates to be enrolled.
Overall, the support for the study and the P.I.
Professor Chon was overwhelming, and it confirms really the expertise and the quality his name is associated with when it comes to liver cancer studies. So overall, we were very welcome and they were extremely interested in Fostrox also as an alternative with another mechanism of action compared to both immunotherapy and TKI. That is usually the one that you can use in this patient population.
So we can go to the next slide. So to summarize the takeaway from this visit, we can conclude that unfortunately, liver cancer continues to be a very common disease in Korea. Despite that, they now have started vaccination. It's still very common, and while there are first-line treatment options now with immune combinations, primarily, there is a high unmet need in subsequent treatment lines, particularly in the second-line setting, where many patients can tolerate second-line treatment. But still there is no optimal treatment.
So the sites are fully committed to the FLEX-HCC study, and it fits very well with a standard treatment for advanced HCC. The majority, an estimated 80%, will have received it. Something like that will have received Tecentriq/Avastin, the immune combination in first line, and almost all of them are using Lenvima in the second line setting.
That's why this trial really fits well in, and most of the sites had no competing studies ongoing in HCC and those who actually had studies ongoing, it was mainly cell therapy or bispecific targeting GPC-3, which I think that all of you are interested in. HCC, I've heard, has been a target that has been discussed for quite a few years now, and we are waiting for the results, but it's mainly in the first-line population and selected patients there.
So the interest in Fostrox is also partly built on the fact that it is an all-comers population. You don't need to do any biomarker testing, and it could be something that is available for more patients than those are selected in the other GPC-3 trials. So high interest.
We can go to the next slide, and I think I'll leave it to you.